Skip to main content

Schistosomiasis

6
Pipeline Programs
4
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
4 programs
3
1
PraziquantelPhase 41 trial
GLA-AFPhase 11 trial
PraziquantelPhase 11 trial
Sm-p80Phase 11 trial
Active Trials
NCT03110757Completed60Est. Nov 2019
NCT01288872Completed47Est. Aug 2013
NCT05292391Completed45Est. Mar 2024
+1 more trials
Hikma
HikmaNJ - Berkeley Heights
1 program
1
praziquantelPhase 31 trial
Active Trials
NCT01558336Completed520Est. Sep 2012
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
PraziquantelPhase 21 trial
Active Trials
NCT03640377Completed354Est. Jun 2024
Merck & Co.
Merck & Co.RAHWAY, NJ
3 programs
BiltricidePHASE_21 trial
Praziquantel 600Mg Oral Tablet x 5PHASE_2_31 trial
L-PZQ ODT 50 mg/kgPHASE_31 trial
Active Trials
NCT02806232Completed444Est. Nov 2018
NCT04115072Completed116Est. Feb 2020
NCT03845140Completed288Est. Oct 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsPraziquantel
Merck & Co.L-PZQ ODT 50 mg/kg
Hikmapraziquantel
Merck & Co.Praziquantel 600Mg Oral Tablet x 5
Human BioSciencesPraziquantel
Merck & Co.Biltricide
Allergy TherapeuticsSm-p80
Allergy TherapeuticsGLA-AF
Allergy TherapeuticsPraziquantel

Clinical Trials (9)

Total enrollment: 1,874 patients across 9 trials

Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis

Start: Apr 2016Est. completion: Dec 20180
Phase 4Withdrawn
NCT03845140Merck & Co.L-PZQ ODT 50 mg/kg

L-PZQ ODT in Schistosoma Infected Children

Start: Sep 2019Est. completion: Oct 2021288 patients
Phase 3Completed
NCT01558336Hikmapraziquantel

Schistosoma Haematobium Infections and Praziquantel

Start: Aug 2008Est. completion: Sep 2012520 patients
Phase 3Completed
NCT04115072Merck & Co.Praziquantel 600Mg Oral Tablet x 5

Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study

Start: Sep 2019Est. completion: Feb 2020116 patients
Phase 2/3Completed

Praziquantel in Children Under Age 4

Start: Feb 2021Est. completion: Jun 2024354 patients
Phase 2Completed

An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)

Start: Jun 2016Est. completion: Nov 2018444 patients
Phase 2Completed

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Start: May 2022Est. completion: Mar 202445 patients
Phase 1Completed

A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults

Start: May 2018Est. completion: Nov 201960 patients
Phase 1Completed

Praziquantel-Pharmacokinetic Study

Start: Jan 2012Est. completion: Aug 201347 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.